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Objectives The purpose of this study was to determine whether alterations in cardiac structure or function contribute
to the increased risk associated with renal impairment after myocardial infarction (MI).
Background Renal impairment is associated with adverse cardiovascular outcomes after MI.
Methods Echocardiography was performed on 603 patients with left ventricular (LV) dysfunction, heart failure (HF),
or both after MI. Patients were grouped according to their estimated glomerular filtration rate (eGFR), and
measures of cardiac structure and function were related to baseline eGFR. The relationship between eGFR
and cardiac structure and function and clinical outcomes of death or HF was assessed with multivariable
Cox regression.
Results Ejection fraction, infarct segment length, right ventricular function, and mitral deceleration time were not influ-
enced by renal function. Patients with reduced eGFR had smaller LV and larger left atrial (LA) volumes and
higher left ventricular mass index (LVMI) and LV mass/LV volume ratio. A greater proportion of the patients with
reduced eGFR had LV hypertrophy. The relationship between eGFR and the outcome of death or HF was attenu-
ated by including baseline differences in LVMI, and both LVMI and LA volume conferred additional prognostic
information in a multivariable model.
Conclusions Renal impairment was associated with smaller LV and larger LA volumes and increased LVMI. Systolic function
was similar when compared with patients with normal renal function. Thus, reduced systolic function cannot
account for worse outcomes in patients with renal impairment after MI. Indirect measures of diastolic function
suggest that diastolic dysfunction might be an important mediator of increased risk in this population.
(J Am Coll Cardiol 2007;50:1238–45) © 2007 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.06.018h
(
p
w
a
v
p
a
p
f
s
ratients with mild to moderate impairment in renal func-
ion are at increased risk for adverse cardiovascular (CV)
utcomes. After myocardial infarction (MI), any renal
ysfunction is associated with increased risk of CV death,
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ccepted June 20, 2007.eart failure (HF), sudden death, stroke, or recurrent MI
1–6). Cardiovascular mortality is 10 to 30 times higher in
atients with end-stage renal disease (ESRD) as compared
ith the general population and approaches 50% at 2 years
fter MI (1). End-stage renal disease is associated with a
ariety of cardiac alterations including left ventricular hy-
ertrophy (LVH), LV dilation, and reduction in systolic
nd diastolic function, with only 16% of new dialysis
atients presenting with normal cardiac morphology and
unction (7,8).
Although patients with reduced renal function are at
ignificantly increased risk of all CV events, including death,
ecurrent MI, and HF after MI, the reasons for this
ncreased risk have been less clear. Increased vascular events
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September 25, 2007:1238–45 eGFR and Cardiac Structure and Function After MIlearly play an important role, but the increased risk of HF
annot be explained by vascular events alone. This raises the
ossibility that alterations in cardiac function might play a
entral role in increased risk of HF development and CV
ortality.
To assess whether alterations in cardiac structure or function
ontribute to the increased risk associated with reduced renal
unction in the post-MI patient, we studied patients en-
olled in the echocardiographic substudy of the VALIANT
VALsartan In Acute myocardial iNfarcTion) study.
ethods
atient population. The VALIANT study was designed to
est the hypothesis that the angiotensin receptor blocker
alsartan, either alone or in combination with the proven
ngiotensin-converting enzyme inhibitor captopril, would
e superior or not inferior to a proven dose of captopril in
educing CV morbidity or mortality after MI (9). Patients
ith an acute MI complicated by HF, LV systolic dysfunc-
ion (ejection fraction [EF] 35% on echocardiography or
40% on contrast angiography), or both were randomly
ssigned between 12 h and 10 days to treatment with either
aptopril (target dose: 50 mg 3 times daily), valsartan (target
ose: 160 mg twice daily), or their combination (target
oses: captopril 50 mg 3 times daily and valsartan 80 mg
wice daily) in a 1:1:1 ratio (9). Patients with a baseline
erum creatinine level of at least 2.5 mg/dl (221 mol/l)
ere excluded (9). The median duration of follow-up
as 24.7 months. A total of 610 patients were enrolled in
he echocardiographic substudy. Patients underwent
-dimensional echocardiography at a mean time of 5.0 
.5 days after the index MI (baseline) and at 1 and 20 months
10). Details of patient characteristics have been previously
escribed. Inclusion and exclusion criteria were identical to
hose of the main VALIANT trial, and the demographics of
he echocardiographic participants were similar to the overall
tudy group but differed from the main cohort minimally with
espect to age and baseline blood pressure (10).
chocardiographic analysis. All echocardiographic stud-
es were analyzed in a core laboratory. Before analysis, 7
atients were excluded because of insufficient echocardio-
raphic images. Echocardiograms were performed at 5 days
baseline) (n  603), 1 month (n  544), and 20 months
fter MI (n  428). A total of 59 patients in the initial
ohort did not have 1-month echocardiograms, including
1 patients who died before the 1-month echocardiogram.
he 20-month echocardiogram was not performed in 175
atients present in the initial cohort, including 98 patients
ho died before the final visit.
Echocardiograms from videotape were digitized and
nalyses were performed on an offline analysis workstation.
he LV endocardial borders were manually traced by a
ingle experienced observer at end-diastole and -systole at
he mitral and papillary short-axis level and apical 4- and a-chamber views from 3 separate
ardiac cycles. The LV volumes
ere derived according to the
odified biplane Simpson’s rule
n the apical 4- and 2-chamber
iews, and EF was calculated in
he standard fashion from LV
nd-diastolic volume (EDV) and
V end-systolic volume (ESV).
nfarct segment length was as-
essed by manually tracing the
kinetic or dyskinetic segment.
ight ventricular (RV) function,
xpressed as the RV fractional
rea change (RVFAC), was as-
essed quantitatively as the per-
ent change in cavity area from
nd-diastole to end-systole. Base-
ine LV mass was calculated by the
merican Society of Echocardiog-
aphy (ASE) recommended for-
ula for estimation of LV mass from LV linear dimensions
nd indexed to body surface area (11). The LVH was consid-
red present when echocardiographically derived baseline left
entricular mass index (LVMI) was 115 g/m2 for men and
95 g/m2 for women (11).
Mitral regurgitation (MR) was categorized by mapping
nd tracing the jet area (obtained with color Doppler
maging) occupying the left atrium in 4- and 2-chamber
iews at end-diastole and -systole from 3 separate cardiac
ycles and was expressed as a proportion of left atrial (LA)
rea. The MR was considered mild when regurgitant jet
rea occupied 5% and 20% of the LA area, moderate
hen 20% and 40%, and severe when 40% (12,13).
he presence of an eccentric jet raised the grade of MR by
degree (14). The LA volume was assessed by the biplane
rea-length method from apical 2- and 4-chamber views at
nd-systole from the frame preceding mitral valve opening.
he left atrial volume index (LAVI) was calculated as LA
olume/body surface area (ml/m2). Mitral flow velocity was
ssessed by pulsed wave Doppler study from the apical
-chamber view, by positioning the sample volume at the tip
f the mitral leaflets.
Echocardiographic measurements were made in triplicate
y a single experienced observer blinded to outcome data
nd treatment assignment with quantitative analysis soft-
are. Reproducibility was assessed after studies were ran-
omly chosen and reanalyzed with the observer blinded to
he initial results. The mean signed differences and the SD
f the differences between measurements were calculated
Bland-Altman method), and the variability was expressed
s the SD of the difference divided by the mean measure-
ent. The coefficient of variability based on the reproduc-
bility assessment was 8.3%, 2.7%, 3.0%, 5.3%, and 1% for
V volume, LV mass, LA volume, RVFAC, and MR
Abbreviations
and Acronyms
EDV  end-diastolic volume
EF  ejection fraction
eGFR  estimated
glomerular filtration rate
ESRD  end-stage renal
disease
ESV  end-systolic volume
HF  heart failure
LAVI  left atrial volume
index
LVH  left ventricular
hypertrophy
LVMI  left ventricular
mass index
MR  mitral regurgitation
RVFAC  right ventricular
fractional area of changessessment, respectively.
E
w
u
D
g
F
m
t
g
m
b
e
S
m
v
o
c
a
b
o
t
p
a
h
w
e
v
p
m
S
c
a
o
b
t
i
s
o
d
a
i
g
p
h
c
(
a
a
t
g
M
w
s
S
T
R
B
e
m
w

l
p
(
M
c
c
d
i
i
d
E
f
e
s
a
i

(
d
T
L
c
h
a
a
0
L
fl
g
m
s
E
c
e
w
C
d
1240 Verma et al. JACC Vol. 50, No. 13, 2007
eGFR and Cardiac Structure and Function After MI September 25, 2007:1238–45stimated glomerular filtration rate (eGFR). Patients
ere categorized according to the eGFR at baseline with the
se of the 4-component Modification of Diet in Renal
isease (MDRD) study equation incorporating age, race,
ender, and serum creatinine level (6,15):
eGFR  186 serum creatinine level in mg/dl1.154

age in years0.203
or women and blacks, the product of this equation was
ultiplied by a correction factor of 0.742 and 1.21, respec-
ively. The distribution of the eGFR was divided into 4
roups (45.0, 45.0 to 59.9, 60.0 to 74.9, and 75.0
l/min/1.73 m2) (6,16). The present stratification of the
aseline eGFR is based on the previous report of Anavekar
t al. (6) from the main VALIANT cohort.
tatistical analysis. Continuous data were expressed as
ean  SD. Among the 4 categories of eGFR, categorical
ariables were analyzed with the chi-square test. Continu-
us variables were compared with the nonparametric Wil-
oxon rank sum test for trend across ordered groups. In
ddition, changes in echocardiographic parameters between
aseline and 20 months were also compared across the 4
rdered groups with the nonparametric Wilcoxon rank sum
est for trend. Multivariate linear regression analysis was
erformed to investigate the relationship between eGFR
nd the echocardiographic parameters adjusting for age,
istory of hypertension, and history of diabetes. Event rates
ere calculated with survival time data and expressed as
vents/100 patient-years. To determine the independent
alue of baseline eGFR, we used a multivariable Cox
roportional hazards model. The primary end point for the
ain VALIANT study was death from any cause (9).
econdary end points included death from CV causes,
ongestive HF, recurrent MI, resuscitation after cardiac
rrest, stroke, and a CV composite of these. Clinical
utcomes including hospital stay for HF were adjudicated
y an independent Clinical Endpoints Committee. Addi-
ionally, for the purpose of this analysis, clinical outcomes
ncluded a composite of death from any cause and hospital
tay for HF, which was defined as the unplanned treatment
f new or worsening HF requiring the use of intravenous
iuretic, inotrope, or vasodilator drugs during any hospital
dmission or overnight stay in a healthcare facility.
The adjustment model included predictors of mortality
dentified from the overall VALIANT study: age (in years),
ender, primary percutaneous transluminal coronary angio-
lasty (PTCA) after MI, atrial fibrillation complicating MI,
istory of diabetes, history of hypertension, prior MI, Killip
lass, and a history of chronic obstructive pulmonary disease
COPD). In addition to the aforementioned risk factors,
djustment was also made for the echocardiographic vari-
ble of interest with each variable entering separately into Mhe model and treatment assignment. The echocardio-
raphic variables were: LV ESV, LVEF, LAVI, ratio of
R area to LA area, RVFAC, and LVMI. All p values
ere 2-sided; p  0.05 was used to determine statistical
ignificance. Statistical analyses were performed with
TATA software, version 8.2 (Stata Corp., College Station,
exas).
esults
aseline eGFR for the 603 patients in the VALIANT
chocardiographic cohort was normally distributed, and the
ean SD eGFR was 71.4 20.5 ml/min/1.73 m2, which
as similar to the nonechocardiographic cohort (eGFR 70.2
21.3). Despite the use of a serum creatinine level of at
east 2.5 mg/dl as an exclusion criterion, 180 (29.9%)
atients met eGFR criteria for chronic kidney disease
eGFR 60 ml/min/1.73 m2) (16).
Reduced eGFR was associated with higher rates of prior
I, prior hypertension, prior diabetes mellitus, and prior
ongestive HF (Table 1). Patients in the lower eGFR
ategories were less likely to be treated with beta-blocker
rugs and less likely to have received coronary revascular-
zation. Although lower eGFR was associated with increas-
ng age and female gender, these variables were used in the
etermination of eGFR.
chocardiographic data. The LVEF, RVFAC, and in-
arct segment lengths were similar across the 4 categories of
GFR (Table 2). Decreasing eGFR was associated with a
ignificantly lower EDV, a higher baseline LAVI (Figs. 1A
nd 1B), and a higher LVMI (Table 2). The LVH increased
n a stepwise fashion with decreasing eGFR (p for trend
0.001), as did the LV mass/EDV ratio (p for trend0.001)
Fig. 1C). A trend toward a lower ESV was also observed with
ecreasing eGFR but did not achieve statistical significance.
he LVMI (p  0.002), LV mass/EDV ratio (p  0.016),
AVI (p  0.024), and MR (p  0.019) remained signifi-
antly associated with reduced eGFR after adjusting for age,
istory of diabetes, and hypertension.
Quantitative assessment of MR by color Doppler was
vailable in 496 patients. Lower eGFR was associated with
higher proportion of patients presenting with MR (p 
.002) after MI and with a higher ratio of MR jet area to
A area (Table 2). There were no differences in transmitral
ow and mitral deceleration time at baseline across the 4
roups (Table 2).
Paired echocardiographic studies between baseline and 20
onths were available in 428 patients. There were no
ignificant differences in the magnitude of the change in LV
DV, LV ESV, and LVEF between patients in either
ategory of eGFR from baseline to 20 months with the
xception of LAVI, which significantly increased in patients
ith reduced eGFR (Table 3).
linical outcomes. In this cohort, 103 (17.1%) patients
ied (93 CV), 63 (10.4%) patients experienced recurrent
I, 17 (2.8%) patients experienced stroke, 95 (15.7%)
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September 25, 2007:1238–45 eGFR and Cardiac Structure and Function After MIatients were hospitalized for HF, and 162 (27%) pa-
ients either died or developed HF. To assess whether
bnormalities of cardiac structure and function could
ccount for the influence of reduced eGFR on death or
evelopment of HF, we created a multivariable Cox
aseline Characteristics of Patients Stratified by eGFR Group
Table 1 Baseline Characteristics of Patients Stratified by eGFR
Characteristic
<45.0
(n  55)
4
(
Age, yrs 72.4 7.6 7
White race, % 100
Female, % 55.3
Medical history, %
MI 41
Hypertension 75
Diabetes mellitus 43
HF 36
eGFR, ml/min/1.73 m2 38.5 6 5
Killip class I, % 74
Blood pressure, mm Hg
Systolic 122.5 15 12
Diastolic 70.4 11 7
Medications at time of randomization, %
Beta-blockers 71
Aspirin 88
Calcium-channel blocker 16
Thrombolytic therapy, %* 29
PTCA, %* 9
alues are presented as mean SD unless otherwise indicated. *The procedure took place in the in
roup.
eGFR  estimated glomerular filtration rate; HF  heart failure; PTCA  percutaneous translum
aseline Echocardiographic Characteristics Stratified by eGFR Gro
Table 2 Baseline Echocardiographic Characteristics Stratified
Echocardiographic Measures
<45.0
(n  55)
45.0
(n 
EDV, ml 113.8 27.5 114.7
ESV, ml 70.0 20.5 70.7
LVEF, % 38.9 5.6 38.8
LVMI, g/m2 110.2 27.8 104.0
LV mass/EDV 1.8 0.5 1.7
LVH, % 60
LAVI, ml/m2 28.4 10.7 25.8
Ratio between MR jet area and LA area 10.7 10.9 10.0
RVFAC, % 41.4 4.2 41.7
Infarct segment length, cm 7.6 2.4 7.0
Doppler
E/A ratio 1.37 0.82 1.33
DT, ms 159.9 46.7 158.9
MR grade, % (n)
No 37 (17/46) 34.3 (
Mild 50 (23/46) 49 (
Moderate or severe 13 (6/46) 16.7 (
alues are presented as mean  SD unless otherwise indicated.
DT  deceleration time; E/A  ratio of early (E wave) and late (A wave) diastolic peak transm
nd-systolic volume; LA  left atrial; LAVI  left atrial volume index; LV  left ventricular; LVEF  left ve
R  mitral regurgitation; RVFAC  right ventricular fractional shortening.roportional hazards model including renal function,
easures of cardiac structure and function (ESV, EF,
AVI, ratio of MR jet area to LA area), and known
linical covariates (age, history of MI, gender, history of
ypertension, Killip class, history of COPD, history of
up
eGFR, ml/min/1.73 m2
9.9
25)
60.0–74.9
(n  185)
>75.0
(n  238) p Value
0.3 64.4 11.6 57.9 11.7 0.005
95.1 93.3 0.72
24.9 20.5 0.005
30 21 0.005
56 49 0.005
20 19 0.005
15 10 0.005
66.9 4 92.2 13 0.001
76 69 0.06
15 120.7 16 120.3 15 0.14
1 70.7 11 70.6 10 0.94
69 81 0.01
92 95 0.19
8 3 0.001
41 43 0.01
14 26 0.005
fter the myocardial infarction (MI) and before the patients were randomly assigned to a treatment
ronary angioplasty.
FR Group
R, ml/min/1.73 m2
60.0–74.9
(n  158)
>75.0
(n  238) p Value (trend)
.5 120.8 33.2 122.0 32.4 0.02
.4 74.5 25.2 74.4 24.4 0.11
39.0 6.2 39.7 5.2 0.16
.4 100.2 30.3 92.4 24.4 0.001
1.6 0.4 1.5 0.4 0.001
29.7 19 0.001
24.2 8.6 22.2 6.7 0.001
8.2 9.3 6.0 7.7 0.001
41.5 4.9 42.3 4.1 0.09
7.4 2.5 7.2 2.4 0.59
4 1.31 0.65 1.32 0.64 0.29
.7 156.2 36.6 156.0 39.0 0.31
2) 47 (72/152) 54 (106/194) 0.002
2) 36 (55/152) 38 (74/194) 0.044
2) 16 (25/152) 7.2 (14/194) 0.037
ow velocities; EDV  end-diastolic volume; eGFR  estimated glomerular filtration rate; ESV Gro
5.0–5
n  1
0.5 1
95.2
46.4
31
62
27
21
3.6 4
79
2.4
0.1 1
67
90
8
31
11
terval aup
by eG
eGF
–59.9
125)
 32
 23
 5.4
 30
 0.5
44
 8.3
 9.5
 3.9
 2.1
 0.7
 37
35/10
50/10
17/10
itral fl
ntricular ejection fraction; LVH  left ventricular hypertrophy; LVMI  left ventricular mass index;
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eGFR and Cardiac Structure and Function After MI September 25, 2007:1238–45iabetes, atrial fibrillation after MI, and primary PTCA
or index MI). Worsening renal function was associated
ith increased risk of death or HF, even after adjusting
or measures of cardiac function, clinical covariates, and
reatment assignment (Table 4). However, the addition
f LVMI to the model attenuated the association be-
ween worsening renal function and death or hospital stay
or HF (Table 3). Both LVMI (HR 1.02/each 1 g/m2
ncrease in LVMI; 95% confidence interval [CI] 1.02 to
.03, overall model chi-square 176.1) and LAVI (HR
.04/each 1 ml/m2 increase in LAVI; 95% CI 1.02 to
.06, overall model chi-square 110.0) conferred addi-
ional prognostic information in a multivariable model
Table 4).
Figure 1 Relationship Between eGFR and EDV, LAVI, LVMI, and
Reduced estimated glomerular filtration rate (eGFR) was significantly associated w
volume (EDV) and increasing left atrial volume index (LAVI), left ventricular mass in
hange in Echocardiographic Measures Stratified by eGFR Group
Table 3 Change in Echocardiographic Measures Stratified by e
eGFR
Echocardiographic
Measures <45 45–59.9
Baseline to 20 months
n 30 78
LAVI, ml/m2 4.2 9.4 5.6 8.1
EDV, ml 1.8 15.4 5.0 18.2
ESV, ml 0.07 14.9 3.0 16.2
LVEF, % 1.5 7.0 0.7 6.7alues are presented as mean  SD.
Abbreviations as in Table 2.iscussion
n this analysis, we assessed the relationship between renal
unction and cardiac structure and function in high-risk
urvivors of MI. The increased risk of CV mortality and
ospital stay for HF in patients with reduced renal function
ould not be explained by reduced systolic function, because
eft (and right) ventricular function was similar across eGFR
ategories. Indeed, we observed that patients with worse
enal function had smaller, more hypertrophied hearts.
ower eGFR was associated with a lower LV EDV and
SV and higher LV mass, LV mass/EDV ratio, and LA
olume (Fig. 1). A greater proportion of the patients in the
ower eGFR category had LVH.
to LV EDV Ratio
wer left ventricular (LV) end-diastolic
VMI), and left ventricular mass (LVM)/LV EDV ratio.
Group
min/1.732
60–74.9 >75.0 p Value (trend)
130 190
1.9 6.3 2.4 6.4 0.039
1.7 16.5 1.8 18.5 0.25
1.4 16.1 1.3 16.9 0.15
2.3 7.7 2.3 7.1 0.31LVM
ith a lo
dex (LGFR
, ml/
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September 25, 2007:1238–45 eGFR and Cardiac Structure and Function After MIA variety of morphological changes have been described
n patients with chronic kidney disease and in patients with
enal failure on renal replacement therapy. These ultrastruc-
ure changes, sometimes collectively referred to as uremic
ardiomyopathy, are characterized by LVH, dilated cardio-
yopathy, and systolic dysfunction (7,8). Left ventricular
bnormalities are extremely common upon initiation of
ialysis, with LVH evident in 40%, LV dilatation in 28%,
nd systolic dysfunction in 16% of all patients starting
ialysis (7).
In spite of extensive knowledge about cardiac structure
nd function in patients with ESRD, the relationship
etween mild reductions in renal function and cardiac
orphology and function has been less clear. In contrast to
he established evidence that ventricular enlargement after
I has been associated with adverse CV outcomes (17–20),
ur data suggest that renal impairment was associated with
maller ventricular volumes, while having a significant
mpact on mortality and HF. Moreover, we observed that
ower eGFR was also associated with larger LA volume
Fig. 1B) and with the presence of MR in a higher
roportion of patients. However, the transmitral Doppler
ndexes of LV diastolic function did not differ in magnitude
mong the categories of eGFR. The LA volume is an
ndirect measure of ventricular pressure and compliance
uring ventricular diastole (21). The LA volume has been
hown to be related to the severity of diastolic dysfunction
nd to be an important risk factor for development of HF in
atients with LV diastolic dysfunction (22–24).
In our study, declining renal function was also strongly
ssociated with a higher proportion of patients presenting
ith LVH (60% for eGFR 45 vs. 19% for eGFR 75)
nd with a higher proportion of patients presenting with a
istory of hypertension (75% for eGFR 45 vs. 48.9% for
GFR75) (Table 1). Left ventricular hypertrophy is likely
o develop in the earliest phases of all forms of renal disease
azard Ratios (95% CI) for All-Cause Mortality and/or Hospital Sta
Table 4 Hazard Ratios (95% CI) for All-Cause Mortality and/or
e
<45.0 45
Death or HF, % 49
Incidence rate/100 patient-yrs (95% CI) 43.0 (29.4–62.6) 29.4 (
Multivariable 2.1 (1.2–2.8); p 0.007 1.8 (1.1–2
Multivariable including treatment
assignment
2.1 (1.2–3.7); p 0.008 1.8 (1.1–2
Multivariable including ESV 2.3 (1.3–4.0); p 0.004 1.8 (1.1–2
Multivariable including LVEF 2.1 (1.2–3.7); p 0.007 1.7 (1.1–2
Multivariable including LAVI 2.1 (1.2–3.7); p 0.011 1.7 (1.0–2
Multivariable including MR
jet area/LA area
2.0 (1.1–3.7); p 0.025 1.9 (1.1–3
Multivariable including LVMI 1.6 (0.9–2.9); p 0.08 1.4 (0.9–2
djusted for age, gender, history of myocardial infarction (MI), history of hypertension, Killip class, h
rimary percutaneous transluminal coronary angioplasty (PTCA) for index MI.
CI  confidence interval; HF  heart failure; other abbreviations as in Table 2.ith a trend toward higher LV mass with declining eGFR e25). Although the pathogenesis of LVH in patients with
enal failure is less clear, hypertension is believed to be a
eading cause of LVH in ESRD, and anemia, along with
olume overload, is thought to play a potential contributory
ole (26). Increased myocardial mass leads to abnormal
assive elastic properties of the myocardium and myocardial
tiffness, reducing chamber compliance and elevating dia-
tolic pressure, which accounts for diastolic dysfunction
27,28). Diastolic filling abnormalities are common in
ypertension, and diastolic dysfunction is believed to be an
mportant pathophysiologic intermediate between hyper-
ension and HF development. (29). An increase in intercar-
iomyocyte fibrosis and myocardial collagen content
30,31), coupled with the alterations in calcium homeostasis
nterfering with myocardial relaxation (32), is also thought
o contribute to LV diastolic dysfunction in patients with
enal dysfunction.
The increased incidence of CV deaths or hospital stays
or HF in patients with poor renal function could be
artially explained by an increase in LV mass. Our obser-
ation of similar baseline EF and infarct segment length
mong different categories of renal function suggests that
he higher risk of mortality and hospital stay for HF in
atients with poor renal function cannot be attributed to
onsequences of larger infarcts. Greater baseline LA vol-
mes, LV mass, and a higher LV mass/LV EDV ratio with
maller ventricular volumes in patients with lower eGFR in
his study suggests that diastolic dysfunction—most likely
receding the MI—could possibly explain the higher risk of
V mortality and HF development in patients with declin-
ng renal function.
Several limitations of this analysis should be noted. First,
e used the MDRD equation for the estimation of GFR.
his is an indirect creatinine-based assessment of renal
unction, and although considered reliable in estimating
FR, it has limitations, because serum creatinine is influ-
HF Stratified by eGFR Group
ital Stay for HF Stratified by eGFR Group
ml/min/1.73 m2
9 60.0–74.9 >75.0
p Value
(Trend)
Overall
Model
Chi-Square
27.6 15.1
9.0) 19.4 (14.8–25.6) 9.7 (7.0–13.5)
 0.015 1.4 (0.9–2.2); p 0.13 Reference 0.003 85.7
 0.018 1.4 (0.9–2.2); p 0.13 Reference 0.004 86.9
 0.017 1.4 (0.9–2.2); p 0.16 Reference 0.002 99.0
 0.20 1.3 (0.8–2.1); p 0.20 Reference 0.007 103.6
 0.045 1.4 (0.8–2.2); p 0.17 Reference 0.013 110.0
 0.014 1.4 (0.8–2.3); p 0.19 Reference 0.014 104.8
 0.17 1.1 (0.7–1.8); p 0.60 Reference 0.07 176.1
f chronic obstructive pulmonary disease (COPD), history of diabetes, atrial fibrillation post-MI, andy for
Hosp
GFR,
.0–59.
38.4
22.1–3
.8); p
.8); p
.9); p
.7); p
.7); p
.2); p
.3); p
istory onced by non-renal factors. The MDRD equation might be
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uch as young patients with type 1 diabetes without mi-
roalbuminuria and in potential kidney donors (33). Second,
chocardiograms were obtained, on average, 5 days after MI
nd as many as 10 days after MI; thus, our baseline
chocardiogram might have occurred after substantial re-
overy of function or after significant ventricular enlarge-
ent, both of which can occur during this time period (34).
hird, although transmitral Doppler indexes in our study
id not differ in magnitude among the categories of eGFR,
hese are poor measures of diastolic function that are highly
ensitive to preload and can change unpredictably as dia-
tolic dysfunction progresses (21,35). More robust nonin-
asive measures of diastolic function, such as tissue Doppler
maging, were unavailable in the majority of centers partic-
pating in the VALIANT study at the time the study began.
inally, our results are predominantly applicable to the
igh-risk cohort of the VALIANT study. We cannot
omment on the potential influence of renal impairment as
ssessed by eGFR in patients with normal LV function after
I, and neither of these findings can be extrapolated to
atients with severe renal dysfunction, because patients with
baseline serum creatinine of2.5 mg/dl (221 mol/l) and
orse degrees of renal function were not included in the
ALIANT study.
In summary, the results of this study suggest that in a
igh-risk cohort of individuals with LV dysfunction after
I, patients with renal impairment are similar to those
ithout renal impairment with respect to global left and
ight ventricular systolic function and infarct segment
ength. Yet those with impaired renal function have smaller
entricular volumes, increased LV mass and mass/volume
atio, and larger LA volumes. Thus, reduced systolic func-
ion alone cannot account for increased CV mortality and
ospital stay for HF in post-MI patients with impaired
enal function. Increased LA volume and LV mass in
atients with impaired renal function suggests that diastolic
ysfunction might be an important mediator of increased
isk of HF development and CV mortality in patients with
enal impairment after MI.
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